(C) 2010

Wiley Periodicals, Inc. J Appl Polym Sci 117: 2428-2435, 2010″
“The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy. We present here preliminary data from 18 patients with follow-up of 6 months. We evaluated seizure frequency at baseline. We used administered Mini Mental State Examination (MMSE), Karnofsky Performance Status (KPS), Barthel index (BI), QOLIE 31P (V2), EORTC QLQ-C30 and Adverse Events Profile. After 6 months, 16 patients were seizure free (88.9%), 2 (11.1%) had reduction in seizure frequency > 50%. Compared to baseline, we observed a worsening of performance (KPS p = 0.011; BI = 0.008) and global www.selleckchem.com/products/urmc-099.html lower cognitive performance (MMSE p = 0.011); distress related to seizure frequency (p = 0.003) and medication effects (p = 0.046) were significantly lower. Levetiracetam

caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious HKI-272 mouse and well tolerated.”
“Tartrate-resistant acid phosphatase isoform 5b (TRACP5b) is a serum bone resorption marker. Our aim was to investigate its utility in monitoring metabolic bone disease.

Serum TRACP5b, C-terminal cross-linking telopeptide of type I collagen, urine N-terminal cross-linking telopeptide of type I collagen and free deoxypyridinoline were measured pre- and post-treatment with a parathyroid hormone analogue [PTH (1-34)] (n = 14) or a bisphosphonate (N-BP) (n = 8). TRACP5b, bone alkaline

phosphatase (bone ALP), 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) were measured in 100 osteoporosis patients on prolonged bisphosphonate therapy.

Changes in TRACP5b were smaller in magnitude but mimicked those of other bone resorption markers. Absolute changes in TRACP5b and the other resorption markers correlated significantly (p < 0.001). In patients on long-term bisphosphonates, TRACP5b and bone ALP levels were not suppressed. Vitamin D status was consistent with the level of supplementation.

TRACP5b has limited utility as a single marker of metabolic bone disease treatment.”
“Transition metal (TM) Co doped SnO2 dilute CB-839 in vitro magnetic semiconductor (DMS) in both nano- and bulk state are prepared by solvothermal and mechanosyhtesis route, respectively. Contraction in unit cell volume of tetragonal rutile SnO2 after Co doping and redshift in energy band gap compared to that of undoped SnO2 ensures the incorporation of smaller Co2+ ions replacing larger host cations Sn4+. Vibrating sample magnetometer measurements show that paramagnetism is the intrinsic magnetic property in single-phase Sn1-xCoxO whereas non-DMS related ferromagnetism is associated only with the corresponding nanostructures.